Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.93 - $6.19
Previous CloseN/A
Volume107.87K
Average Volume (3M)518.92K
Market Cap
$318.69M
Enterprise Value$232.03M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Feb 05, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding57,943,066
10 Day Avg. Volume867,137
30 Day Avg. Volume518,917
Standard Deviation0.25
R-Squared0.00299
Alpha0.00422
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.45K
Enterprise Value/Ebitda-3.25
Forecast
1Y Price Target
$12.33Price Target Upside151.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Rezolute News
PremiumCompany Announcements
Rezolute Advances SunRIZE Study for Hypoglycemia Treatment
PremiumCompany Announcements
Rezolute Highlights Promising Phase 2 Ersodetug Results
PremiumCompany Announcements
Rezolute Gains FDA Breakthrough Designation for Ersodetug---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressErsodetug received Breakthrough Therapy Designation, which should help drive rapid enrollment in the US sites.
Financial PositionRZLT has $117.8M in cash, providing financial runway through the second quarter of 2026.
Safety And EfficacyErsodetug is emerging as the preferred treatment option in standard-of-care refractory or intolerant congenital hyperinsulinism (cHI) and likely moving to first-line treatment, enabled by differentiated safety.
Bears Say
Financial NeedsRezolute is not generating revenue and has capital needs that exceed current cash balance.
Potential DilutionRezolute is likely to need to raise additional capital, indicating potential dilution risks.
Trial RisksAn interim analysis for the sunRIZE trial is expected to have three potential outcomes, including futility and trial discontinuation.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $0.93 and its highest was $6.18 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $318.69M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Feb 05, 2025 which is 5 days ago.
How were Rezolute’s earnings last quarter?
Currently, no data Available
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.25.
How many shares outstanding does Rezolute have?
Rezolute has 57,943,066 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
---
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (151.12% Upside)
$12.33 (151.12% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 37.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $137.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
476.00%
12-Months-Change
Fundamentals
Return on Equity
-63.88%
Trailing 12-Months
Asset Growth
9.22%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
---
RZLT Stock 12 Month Forecast
Average Price Target
$12.33
▲(151.12% Upside)
Technical Analysis
Best Analysts Covering RZLT
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+68.48%
reiterated a buy rating 5 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +68.48% per trade.
---